Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies

Abstract

The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma, and in healthy individuals. Data from our study showed significantly decreased serum DPPIV activity and a significant decrease in the percentage of: CD26 + lymphocytes, CD26 + overall white blood cells and lymphocytes in patients with NHL in comparison to healthy controls. Patients with leukemia had a statistically significant lower activity of DPPIV in serum and significant decrease in the percentage of CD26 + lymphocytes in relation to healthy controls. Furthermore, significantly decreased DPPIV serum activity associated with a significantly reduced percentage of CD26 + overall white blood cells and percentage of lymphocytes was found in patients with multiple myeloma when compared to the healthy control group. The obtained results indicate that immune disturbances that can occur in hematological malignancies might be related to the decreased expression and activity of CD26/DPPIV that we observed.

CD26 Expression in Mature B-cell Neoplasms and its Prognostic Impact on B-Cell Chronic Lymphocytic Leukemia

“…CD26 was positive in 50, 85.7, 56.5, 75%, in CLL, HCL, CD5 negative LPD and MM respectively. This was confirmed by other studies [16][17][18]. Previous studies have reported that HCL and B-CLL can express high levels of ADA and CD26.…”

“…Suggesting that their dramatic response to 2-deoxycoformycin and 2-chlorodeoxyadenosine, known inhibitors of ADA, relates to their surface expression of the ADA-CD26 complex [18,19]. Nishida et al reported that CD26 is intensely expressed in activated osteoclasts in MM, but not in MM cells themselves, the direct interaction between MM cells and OCs results in the up-regulation of CD26 expression in MM cells [17].…”

CD26/DPP4 - a potential biomarker and target for cancer therapy

“…Moreover, sDPP4 activity was decreased in CTCL patients, and thus it could a possible marker for disease severity (Miyagaki et al, 2013;Narducci et al, 2006). Similar findings were also reported for NHL, leukemia and MM (Matić et al, 2013).…”

“…Likewise, a decreased plasma sCD26/DPP4 activity was described in patients with CTCL ( 11Sézary syndrome patients and 7 mycosis fungoides patients) compared to controls (Narducci et al, 2006). Similarly, another study examining sCD26/DPP4 activity in serum, expression on lymphocytes and total white blood cells in different hematological malignancies, including non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, leukemia (including patients with AML, ALL and CLL), plasmacytoma and multiple myeloma (MM), reported a decrease in enzymatic activity in NHL, leukemia and MM (Matić et al, 2013). In addition, a decrease in the percentage of CD26 + lymphocytes has been observed in NHL and leukemia.…”

Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis

“…It has been shown that DPPIV plays a crucial role in T cell activation and immune regulation [3]. Disturbed activity of this enzyme, its concentration in serum [2] and expression on different cell types, were found in various conditions including malignant [4,5], autoimmune, and inflammatory diseases [6].…”